跳至主要内容
临床试验/TCTR20200305003
TCTR20200305003尚未招募1 期

Effect of Astragalus membranaceus (Fisch.) Bunge extract containing Astragaloside IV on renal function and proteinuria in patients with diabetic nephropathy

FAME Pharmaceuticals Industry Co., Ltd.0 个研究点目标入组 60 人开始时间: 2020年3月5日最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 0 N/A (No limit)(—)
性别
All

入选标准

  • 1.Diabetic nephropathy patients (new cases) with urinary albumin-to-creatinine ratio ≥30 mg/g and/or sustained reduction in eGFR below 60 ml/min/1.73 m2
  • 2.Aged 18 years and above

排除标准

  • 1.Prior history of taking Astragalus membranaceus extract and ACEI/ARB
  • 2.Patients with history of allergy to Astragalus membranaceus
  • 3.Pregnant women and lactating mothers
  • 4.Patients with the history of autoimmune diseases
  • 5.Patients with the history of other causes of nephropathy such as obstructive uropathy, hypertension, SLE, glomerulonephritis and polycystic kidney disease
  • 6.Patients on steroids and/or immunosuppressive agents
  • 7.Patients with acute renal failure and renal transplant recipient

研究者

发起方
FAME Pharmaceuticals Industry Co., Ltd.

相似试验